RU97100300A - Контролируемое освобождение стероидов из сахарных покрытий - Google Patents
Контролируемое освобождение стероидов из сахарных покрытийInfo
- Publication number
- RU97100300A RU97100300A RU97100300/14A RU97100300A RU97100300A RU 97100300 A RU97100300 A RU 97100300A RU 97100300/14 A RU97100300/14 A RU 97100300/14A RU 97100300 A RU97100300 A RU 97100300A RU 97100300 A RU97100300 A RU 97100300A
- Authority
- RU
- Russia
- Prior art keywords
- steroid
- sugar coating
- pharmaceutical tablet
- sugar
- hormonal
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title claims 11
- 238000009495 sugar coating Methods 0.000 claims 8
- 239000003826 tablet Substances 0.000 claims 7
- 230000003054 hormonal Effects 0.000 claims 6
- -1 medrogeston Chemical compound 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229940088597 Hormone Drugs 0.000 claims 2
- WWYNJERNGUHSAO-XUDSTZEESA-N Previfem Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229960004400 levonorgestrel Drugs 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- 229940022663 Acetate Drugs 0.000 claims 1
- 229960003839 Dienestrol Drugs 0.000 claims 1
- NFDFQCUYFHCNBW-SCGPFSFSSA-N Dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 claims 1
- 229960005309 Estradiol Drugs 0.000 claims 1
- 229960001348 Estriol Drugs 0.000 claims 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N Estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims 1
- 229960003399 Estrone Drugs 0.000 claims 1
- AOXRBFRFYPMWLR-XGXHKTLJSA-N Ethylestrenol Chemical compound C1CC2=CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 AOXRBFRFYPMWLR-XGXHKTLJSA-N 0.000 claims 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 1
- 229960005352 Gestodene Drugs 0.000 claims 1
- SIGSPDASOTUPFS-XUDSTZEESA-N Gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Hiestrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims 1
- 229960004296 Megestrol Acetate Drugs 0.000 claims 1
- IMSSROKUHAOUJS-MJCUULBUSA-N Mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims 1
- 229960001390 Mestranol Drugs 0.000 claims 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 claims 1
- KIQQMECNKUGGKA-NMYWJIRASA-N Norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims 1
- 229940053938 Norgestrel Drugs 0.000 claims 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 claims 1
- JUNDJWOLDSCTFK-MTZCLOFQSA-N Trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 claims 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960003309 dienogest Drugs 0.000 claims 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 230000001076 estrogenic Effects 0.000 claims 1
- 229960002568 ethinylestradiol Drugs 0.000 claims 1
- 229960001460 ethylestrenol Drugs 0.000 claims 1
- 229960002899 hydroxyprogesterone Drugs 0.000 claims 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 1
- 229960001566 methyltestosterone Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960000417 norgestimate Drugs 0.000 claims 1
- 229960000464 oxandrolone Drugs 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 239000007940 sugar coated tablet Substances 0.000 claims 1
- 229950008546 trimegestone Drugs 0.000 claims 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 claims 1
Claims (7)
1. Фармацевтическая таблетка, включающая внутреннее спрессованное ядро и наружное сахарное покрытие, где указанное спрессованное ядро необязательно содержит одно или более нестероидных фармакологически-активных средств, которые обычно применяют в сочетании с гормональным стероидом, отличающаяся тем, что указанное сахарное покрытие таблетки содержит гормональный стероид и микрокристаллическую целлюлозу в количестве, регулирующем скорость освобождения гормонального стероида.
2. Фармацевтическая таблетка, включающая не содержащее лекарственное средство спрессованное ядро и сахарное покрытие, отличающаяся тем, что указанное сахарное покрытие включает гормональный стероид и микрокристаллическую целлюлозу в количестве, регулирующем скорость освобождения гормонального стероида.
3. Фармацевтическая таблетка по п. 1, в которой указанный сахар, присутствующий в указанном сахарном покрытии, представляет сахарозу.
4. Фармацевтическая таблетка по п. 1, в которой указанный гормональный стероид, присутствующий в указанном сахарном покрытии, представляет медроксипрогестерон ацетат, левоноргестрел, гестоден, медрогестон, эстрадиол, эстриол, эфинилэстрадиол, местранол, эстрон, диенестрол, гексэстрол, диэтилстильбэстрол, прогестерон, дезогестрел, норгестимат, гидроксипрогестерон, норэфиндрон, норэфиндон ацетат, норгестрел, мегестрол ацетат, метилтестостерон, этилэстренол, метандиенон, оксандролон, тримегестон или диеногест.
5. Фармацевтическая таблетка по п. 1, в которой указанный гормональный стероид, присутствующий в сахарном покрытии, представляет RU-486, онапристон ZK-137316, ORG-31730 или HRP-2000.
6. Фармацевтическая таблетка по п. 1, в которой указанное сахарное покрытие включает сахарозу от около 0,1% до около 3% микрокристаллической целлюлозы, по массе, поливинилпирролидон в количестве от 0 до около 5% по массе и гормональный стероид в количестве от около 0,1% до около 20% по массе.
7. Фармацевтическая таблетка по п. 1, в которой указанное сахарное покрытие содержит эстрогенный стероид и прогестогенный стероид.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/637,139 US5759577A (en) | 1995-01-17 | 1996-04-24 | Controlled release of steroids from sugar coatings |
| US08/637139 | 1996-04-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU97100300A true RU97100300A (ru) | 1999-02-10 |
| RU2181586C2 RU2181586C2 (ru) | 2002-04-27 |
Family
ID=24554700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU97100300/14A RU2181586C2 (ru) | 1996-04-24 | 1997-01-08 | Контролируемое освобождение стероидов из сахарных покрытий |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US5759577A (ru) |
| EP (1) | EP0803250B1 (ru) |
| JP (1) | JP4112648B2 (ru) |
| KR (1) | KR100482913B1 (ru) |
| CN (1) | CN1149982C (ru) |
| AR (1) | AR005659A1 (ru) |
| AT (1) | ATE218326T1 (ru) |
| AU (1) | AU722188B2 (ru) |
| BR (1) | BR9701904A (ru) |
| CA (1) | CA2194428A1 (ru) |
| CO (1) | CO4780019A1 (ru) |
| CY (1) | CY2302B1 (ru) |
| CZ (1) | CZ289762B6 (ru) |
| DE (1) | DE69621588T2 (ru) |
| DK (1) | DK0803250T3 (ru) |
| EG (1) | EG23911A (ru) |
| ES (1) | ES2179165T3 (ru) |
| HK (1) | HK1003870A1 (ru) |
| HU (1) | HU226397B1 (ru) |
| ID (1) | ID16611A (ru) |
| IL (1) | IL119976A (ru) |
| IS (1) | IS1886B (ru) |
| MY (1) | MY115223A (ru) |
| NO (1) | NO315354B1 (ru) |
| NZ (1) | NZ299823A (ru) |
| PL (1) | PL187255B1 (ru) |
| PT (1) | PT803250E (ru) |
| RU (1) | RU2181586C2 (ru) |
| SG (1) | SG64407A1 (ru) |
| SI (1) | SI0803250T1 (ru) |
| SK (1) | SK282484B6 (ru) |
| TR (1) | TR199700052A3 (ru) |
| TW (1) | TW487583B (ru) |
| UA (1) | UA59333C2 (ru) |
| UY (1) | UY24527A1 (ru) |
| ZA (1) | ZA9610424B (ru) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| ES2152671T3 (es) * | 1996-05-01 | 2001-02-01 | Us Gov Health & Human Serv | Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales. |
| CN1236435A (zh) * | 1996-11-07 | 1999-11-24 | 奥索·麦克尼尔药品公司 | 一种固体甾族药物制剂的溶解测试方法 |
| US5985325A (en) * | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US6723342B1 (en) | 1999-02-08 | 2004-04-20 | Fmc Corporation | Edible coating composition |
| US6432448B1 (en) | 1999-02-08 | 2002-08-13 | Fmc Corporation | Edible coating composition |
| US6500462B1 (en) | 1999-10-29 | 2002-12-31 | Fmc Corporation | Edible MCC/PGA coating composition |
| FR2801218B1 (fr) * | 1999-11-23 | 2001-12-28 | Hoechst Marion Roussel Inc | Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant |
| AT500063A1 (de) | 1999-11-23 | 2005-10-15 | Sandoz Ag | Beschichtete tablettenkerne |
| US6399591B1 (en) * | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
| US7989436B2 (en) | 2003-07-23 | 2011-08-02 | Duramed Pharmaceuticals, Inc. | Estrogenic compounds and pharmaceutical formulations comprising the same |
| US6855703B1 (en) | 2000-03-10 | 2005-02-15 | Endeavor Pharmaceuticals | Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| US6660726B2 (en) | 2000-03-10 | 2003-12-09 | Endeavor Pharmaceuticals | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same |
| US7459445B2 (en) * | 2000-03-10 | 2008-12-02 | Duramed Pharmaceuticals, Inc. | Estrogenic compounds and topical pharmaceutical formulations of the same |
| US20010034340A1 (en) * | 2000-03-20 | 2001-10-25 | American Home Products Corporation | Hormone replacement therapy |
| IL155959A0 (en) | 2000-11-28 | 2003-12-23 | Fmc Corp | Edible pga (propylene glycol alginate) coating composition |
| JP4969747B2 (ja) * | 2001-01-19 | 2012-07-04 | 武田薬品工業株式会社 | 錠剤フィルムコーティング用組成物 |
| EA200301022A1 (ru) * | 2001-03-16 | 2004-02-26 | Уайт | Гормональная заместительная терапия |
| TW200306196A (en) * | 2002-04-03 | 2003-11-16 | Wyeth Corp | Hormone replacement therapy |
| TW200306846A (en) * | 2002-04-03 | 2003-12-01 | Wyeth Corp | Hormone replacement therapy |
| TW200306851A (en) * | 2002-04-29 | 2003-12-01 | Wyeth Corp | Hormone replacement therapy |
| TW200400040A (en) * | 2002-05-17 | 2004-01-01 | Wyeth Corp | Hormone replacement therapy |
| US20060111577A1 (en) * | 2003-02-28 | 2006-05-25 | Kim Hyun K | Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates |
| US6992075B2 (en) * | 2003-04-04 | 2006-01-31 | Barr Laboratories, Inc. | C(14) estrogenic compounds |
| CA2521471A1 (en) * | 2003-04-11 | 2004-10-28 | Barr Laboratories, Inc. | Methods of administering estrogens and progestins |
| EP2112920B1 (en) | 2003-06-26 | 2018-07-25 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| ES2933479T3 (es) * | 2003-09-29 | 2023-02-09 | Novo Nordisk Healthcare Ag | Estabilidad mejorada de formulaciones de progestágenos |
| US20050271724A1 (en) * | 2004-06-07 | 2005-12-08 | Wyeth | Sugar coatings and methods therefor |
| US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| US20060127451A1 (en) * | 2004-09-23 | 2006-06-15 | Michael Augello | Coating composition |
| WO2006084082A1 (en) * | 2005-02-03 | 2006-08-10 | Duramed Pharmaceuticals, Inc. | Compositions of unconjugated estrogens and methods for their use |
| FR2883179B1 (fr) | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
| TW200738283A (en) * | 2005-06-29 | 2007-10-16 | Wyeth Corp | Formulations of conjugated estrogens and bazedoxifene |
| WO2007058645A1 (en) * | 2005-11-15 | 2007-05-24 | Wm. Wrigley Jr. Company | Tablets comprising a core and a medicament-containing coating for buccal release |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| CA2648280C (en) * | 2006-04-03 | 2014-03-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| JP2010509350A (ja) * | 2006-11-07 | 2010-03-25 | ワイス エルエルシー | 糖コーティングおよびその方法 |
| JP2010511062A (ja) * | 2006-11-29 | 2010-04-08 | ワイス エルエルシー | エストロゲン／ｓｅｒｍおよびエストロゲン／プロゲスチン二層錠剤 |
| US8512745B2 (en) * | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
| FR2997628B1 (fr) * | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone |
| KR102221846B1 (ko) * | 2014-04-07 | 2021-02-26 | 영진약품 주식회사 | 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 |
| US20170196816A1 (en) * | 2014-06-02 | 2017-07-13 | Nipro Corporation | Laser-printable tablet, and method for manufacturing the same |
| MX2017005163A (es) | 2014-11-17 | 2018-01-18 | Arno Therapeutics Inc | Composiciones de liberación prolongada de onapristona y métodos. |
| BR112018005999A2 (pt) | 2015-09-25 | 2019-01-08 | Context Biopharma Inc | métodos para a produção de intermediários de onapristona |
| CN108883067B (zh) | 2015-12-15 | 2021-03-09 | 康特斯生物制药公司 | 非晶奥那司酮组合物及其制备方法 |
| US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4154820A (en) * | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
| US4191741A (en) * | 1978-09-22 | 1980-03-04 | Eli Lilly And Company | Removable drug implant |
| US4248856A (en) * | 1979-07-10 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4309405A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4309404A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4425339A (en) * | 1981-04-09 | 1984-01-10 | Syntex (U.S.A.) Inc. | Treatment of menopausal symptoms |
| US4390531A (en) * | 1981-08-10 | 1983-06-28 | Syntex Pharmaceuticals International Ltd. | Method of contraception using peak progestogen dosage |
| US4826831A (en) * | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
| GB8403360D0 (en) * | 1984-02-08 | 1984-03-14 | Erba Farmitalia | Pharmaceutical compositions |
| US4755386A (en) * | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5208225A (en) * | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
| US4927816A (en) * | 1987-08-20 | 1990-05-22 | Ester George C | Formulae and methods for sublingual ingestion of natural progesterone |
| US5108995A (en) * | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
| IT1227626B (it) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
| DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
| JP2542122B2 (ja) * | 1990-04-18 | 1996-10-09 | 旭化成工業株式会社 | 球状核、球形顆粒およびその製造方法 |
| US5223268A (en) * | 1991-05-16 | 1993-06-29 | Sterling Drug, Inc. | Low solubility drug-coated bead compositions |
| WO1994009762A1 (en) * | 1992-11-05 | 1994-05-11 | Merck & Co., Inc. | Drug delivery device |
| US5547948A (en) * | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
-
1996
- 1996-04-24 US US08/637,139 patent/US5759577A/en not_active Expired - Lifetime
- 1996-11-14 HU HU9603151A patent/HU226397B1/hu unknown
- 1996-11-14 IS IS4385A patent/IS1886B/is unknown
- 1996-11-19 AU AU71819/96A patent/AU722188B2/en not_active Expired
- 1996-11-21 PT PT96308424T patent/PT803250E/pt unknown
- 1996-11-21 ES ES96308424T patent/ES2179165T3/es not_active Expired - Lifetime
- 1996-11-21 AT AT96308424T patent/ATE218326T1/de active
- 1996-11-21 SI SI9630399T patent/SI0803250T1/xx unknown
- 1996-11-21 DK DK96308424T patent/DK0803250T3/da active
- 1996-11-21 DE DE69621588T patent/DE69621588T2/de not_active Expired - Lifetime
- 1996-11-21 EP EP96308424A patent/EP0803250B1/en not_active Expired - Lifetime
- 1996-11-25 MY MYPI96004928A patent/MY115223A/en unknown
- 1996-11-26 NZ NZ299823A patent/NZ299823A/en not_active IP Right Cessation
- 1996-11-27 SG SG1996011442A patent/SG64407A1/en unknown
- 1996-12-11 ZA ZA9610424A patent/ZA9610424B/xx unknown
-
1997
- 1997-01-06 CA CA002194428A patent/CA2194428A1/en not_active Abandoned
- 1997-01-07 IL IL11997697A patent/IL119976A/xx not_active IP Right Cessation
- 1997-01-08 RU RU97100300/14A patent/RU2181586C2/ru active
- 1997-01-09 CZ CZ199768A patent/CZ289762B6/cs not_active IP Right Cessation
- 1997-01-09 NO NO19970094A patent/NO315354B1/no not_active IP Right Cessation
- 1997-01-13 PL PL97317923A patent/PL187255B1/pl unknown
- 1997-01-14 SK SK55-97A patent/SK282484B6/sk not_active IP Right Cessation
- 1997-01-17 AR ARP970100205A patent/AR005659A1/es active IP Right Grant
- 1997-01-20 KR KR1019970001419A patent/KR100482913B1/ko not_active IP Right Cessation
- 1997-01-21 TW TW086100602A patent/TW487583B/zh not_active IP Right Cessation
- 1997-01-23 CO CO97002984A patent/CO4780019A1/es unknown
- 1997-01-24 TR TR97/00052A patent/TR199700052A3/tr unknown
- 1997-01-26 EG EG7197A patent/EG23911A/xx active
- 1997-01-28 UA UA97010160A patent/UA59333C2/ru unknown
- 1997-02-05 CN CNB971012318A patent/CN1149982C/zh not_active Expired - Lifetime
- 1997-02-07 JP JP02488197A patent/JP4112648B2/ja not_active Expired - Lifetime
- 1997-03-03 ID IDP970654A patent/ID16611A/id unknown
- 1997-04-23 UY UY24527A patent/UY24527A1/es not_active IP Right Cessation
- 1997-04-23 BR BR9701904A patent/BR9701904A/pt active IP Right Grant
-
1998
- 1998-04-16 HK HK98103192A patent/HK1003870A1/xx not_active IP Right Cessation
-
2002
- 2002-11-29 CY CY0200065A patent/CY2302B1/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU97100300A (ru) | Контролируемое освобождение стероидов из сахарных покрытий | |
| KR970069031A (ko) | 당 제피로부터 스테로이드의 방출이 조절되는 약제학적 정제 | |
| RU96100843A (ru) | Композиция на основе сахара для нанесения на таблетку, прессованная таблетка | |
| US6043234A (en) | Method for treating endometriosis or leiomyomata uteri with a competitive progesterone antagonist and a gestagen | |
| US6225297B1 (en) | Combination contraceptive | |
| Sitruk-Ware et al. | Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills | |
| US5719136A (en) | Combination of progesterone antagonists and antiestrogens with partial agonistic action for hormone substitution therapy for perimenopausal and postmenopausal women | |
| KR960028919A (ko) | 당 피막으로부터 스테로이드의 조절된 방출 | |
| Sitruk-Ware | New progestogens: a review of their effects in perimenopausal and postmenopausal women | |
| US5633242A (en) | Pharmaceuticals for contraception/hormone substitution containing a biogenous estrogen component | |
| EP0792152B1 (en) | Methods of contraception | |
| RU98101254A (ru) | Фармацевтический комбинированный препарат, комплект инструмента и метод гормональной контрацепции | |
| JP2008515909A5 (ru) | ||
| NO179311B (no) | Flerfasekombinasjons- og kontraseptiv pakke | |
| CA2057528A1 (en) | Low estrogen oral contraceptives | |
| JP2007535519A5 (ru) | ||
| US6143754A (en) | Competitive progesterone antagonist for demand-oriented female birth control | |
| US20050064031A1 (en) | Combination contraceptive, kits that contain the latter, and a method that uses the latter | |
| US20010016578A1 (en) | Compositions and methods for contraception and for treatment of benign gynecological disorders | |
| WO1998004246A3 (en) | Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen | |
| RU2003107072A (ru) | Применение гормональной композиции, содержащей сочетание эстрогена и прогестагена | |
| NZ334876A (en) | Hormonal composition consisting of an estrogenic derivative and a progestative agent | |
| CA2410993A1 (en) | Starter kit for low dose oral contraceptives | |
| Pelissier et al. | Progestogen contraception using chlormadinone acetate in women presenting high vascular risk.(A gynecoendocrine, metabolic and vascular study) | |
| Křepelka | Estetrol and the possibilities of its clinical use |